Nrx pharmaceuticals, inc. (nasdaq: nrxp) regains compliance with nasdaq minimum market value of listed securities requirement

Company received written notice from the nasdaq listing qualifications staff stating that the company regained compliance with the applicable nasdaq minimum market value of listed securities continued listing requirement nasdaq stated that the matter is now closed wilmington, del. , jan. 21, 2025 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx", the "company"), a clinical-stage biopharmaceutical company, today announced that on january 17, 2025, it received written notice from the nasdaq listing qualifications staff (the "staff") stating that the company regained compliance with the market value of listed securities ("mvls") requirement, as set forth in nasdaq listing rule 5550(b)(2) (the "rule") for continued listing on the nasdaq capital market, and the matter is now closed.
NRXP Ratings Summary
NRXP Quant Ranking